Dashboard
Manage Tickers

INCYINCYTE CORP

Nasdaq incyte.com


$ 65.17 $ -1.26 (-1.9 %)    

Wednesday, 18-Sep-2024 15:59:53 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 472.49 $ -2.05 (-0.43 %)
DIA $ 416.26 $ -1.07 (-0.26 %)
SPY $ 562.20 $ -1.67 (-0.3 %)
TLT $ 99.62 $ -1.25 (-1.24 %)
GLD $ 235.53 $ -1.83 (-0.77 %)
$ 65.17
$ 65.21
$ 65.16 x 100
-- x --
$ 64.49 - $ 66.07
$ 50.27 - $ 70.36
2,858,106
na
12.55B
$ 0.53
$ 129.01
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-30-2024 06-30-2024 10-Q
2 04-30-2024 03-31-2024 10-Q
3 02-13-2024 12-31-2023 10-K
4 10-31-2023 09-30-2023 10-Q
5 08-01-2023 06-30-2023 10-Q
6 05-02-2023 03-31-2023 10-Q
7 02-07-2023 12-31-2022 10-K
8 11-01-2022 09-30-2022 10-Q
9 08-02-2022 06-30-2022 10-Q
10 05-03-2022 03-31-2022 10-Q
11 02-08-2022 12-31-2021 10-K
12 11-02-2021 09-30-2021 10-Q
13 08-03-2021 06-30-2021 10-Q
14 05-04-2021 03-31-2021 10-Q
15 02-09-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-04-2020 06-30-2020 10-Q
18 05-05-2020 03-31-2020 10-Q
19 02-13-2020 12-31-2019 10-K
20 10-30-2019 09-30-2019 10-Q
21 07-30-2019 06-30-2019 10-Q
22 04-30-2019 03-31-2019 10-Q
23 02-14-2019 12-31-2018 10-K
24 10-30-2018 09-30-2018 10-Q
25 07-31-2018 06-30-2018 10-Q
26 05-01-2018 03-31-2018 10-Q
27 02-15-2018 12-31-2017 10-K
28 10-31-2017 09-30-2017 10-Q
29 08-01-2017 06-30-2017 10-Q
30 05-04-2017 03-31-2017 10-Q
31 02-14-2017 12-31-2016 10-K
32 11-01-2016 09-30-2016 10-Q
33 08-09-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 02-12-2016 12-31-2015 10-K
36 11-03-2015 09-30-2015 10-Q
37 08-04-2015 06-30-2015 10-Q
38 04-30-2015 03-31-2015 10-Q
39 02-17-2015 12-31-2014 10-K
40 10-30-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Incyte, Syndax Report Publication Of Data ...
09/18/2024 21:20:03

incyte-downgraded---analyst-notes-intense-competition-particularly-in-larger-markets
Incyte Downgraded - Analyst Notes Intense ...
09/18/2024 18:44:19

Truist Securities has downgraded Incyte due to concerns over Jakafi's patent expiration in 2028. Jakafi, Incyte's top-s...

truist-securities-downgrades-incyte-to-hold-lowers-price-target-to-74
Truist Securities Downgrades Incyte to Hol...
09/18/2024 11:56:57

Truist Securities analyst Srikripa Devarakonda downgrades Incyte (NASDAQ:INCY) from Buy to Hold and lowers the price target ...

jmp-securities-reiterates-market-perform-on-incyte
JMP Securities Reiterates Market Perform o...
09/17/2024 16:22:31

JMP Securities analyst Reni Benjamin reiterates Incyte (NASDAQ:INCY) with a Market Perform.

guggenheim-maintains-buy-on-incyte-raises-price-target-to-92
Guggenheim Maintains Buy on Incyte, Raises...
09/16/2024 16:45:26

Guggenheim analyst Michael Schmidt maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $86 to $92.

cantor-fitzgerald-reiterates-neutral-on-incyte
Cantor Fitzgerald Reiterates Neutral on In...
09/16/2024 12:29:32

Cantor Fitzgerald analyst Eric Schmidt reiterates Incyte (NASDAQ:INCY) with a Neutral.

b-of-a-securities-maintains-neutral-on-incyte-raises-price-target-to-68
B of A Securities Maintains Neutral on Inc...
09/16/2024 12:19:53

B of A Securities analyst Tazeen Ahmad maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $66 to...

reported-saturday-incyte-announced-results-from-phase-3-pod1um-303interaact2-trial-of-retifanlimab-zynyz-in-combination-with-platinum-based-chemotherapy-carboplatinpaclitaxel-for-inoperable-locally-recurrent-or-metastatic-squamous-cell-anal-carcinoma
Reported Saturday, Incyte Announced Result...
09/16/2024 09:23:30

Phase 3 POD1UM-303/InterAACT2 trial met primary endpoint of progression-free survival and demonstrated improvement across secon...

reported-saturday-incyte-unveils-results-for-cdk2-inhibitor-incb123667-in-advanced-solid-tumors-ovarian-cancer-among-highlighted
Reported Saturday, Incyte Unveils Results ...
09/16/2024 07:58:52

New antitumor response data from a range of doses and regimens unveiled today at Incyte investor event These results build u...

cantor-fitzgerald-reiterates-neutral-on-incyte
Cantor Fitzgerald Reiterates Neutral on In...
09/09/2024 17:09:02

Cantor Fitzgerald analyst Eric Schmidt reiterates Incyte (NASDAQ:INCY) with a Neutral.

Core News & Articles
Eli Lilly And EVA Pharma Entered Into An A...
09/04/2024 10:06:33

Discovered By Incyte And Licensed To Lilly, Baricitinib Is For The Treatment Of Rheumatoid Arthritis, Alopecia Areata, Atopic D...

incyte-stock-a-deep-dive-into-analyst-perspectives-9-ratings
Incyte Stock: A Deep Dive Into Analyst Per...
09/03/2024 15:00:24

rbc-capital-reiterates-sector-perform-on-incyte-maintains-67-price-target
RBC Capital Reiterates Sector Perform on I...
09/03/2024 13:30:47

RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $67 price target.

incyte-to-present-late-breaking-phase-3-results-for-retifanlimab-and-initial-data-from-phase-1-cdk2-inhibitor-program-at-the-esmo-congress-2024
Incyte To Present Late-Breaking Phase 3 Re...
08/21/2024 15:41:11

- Presidential Symposium to feature Phase 3 retifanlimab (Zynyz®) results in squamous cell anal carcinoma (SCAC); filing of sup...

incyte-seeks-expanded-fda-approval-for-lymphoma-drug-after-releasing-promising-topline-data-from-late-stage-study
Incyte Seeks Expanded FDA Approval For Lym...
08/16/2024 13:29:34

Incyte's Phase 3 inMIND trial of Monjuvi (tafasitamab) combined with lenalidomide and rituximab meets primary endpoints in ...

incyte-announces-topline-results-from-study-of-tafasitamab-met-its-primary-endpoint-of-progression-free-survival-in-relapsed-or-refractory-follicular-lymphoma-the-secondary-endpoint-of-pfs-results-by-blinded-independent-review-are-consistent-with-investigator-based-pfs-results-no-new-safety-signals-with-tafasitamab-were-observed
Incyte Announces Topline Results From Stud...
08/15/2024 20:34:33

- Phase 3 inMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®) or placebo in combination with lenalidomide...

analyst-expectations-for-incytes-future
Analyst Expectations For Incyte's Future
08/15/2024 20:01:41

fda-approves-incytesyndax-partnered-drug-for-chronic-graft-versus-host-disease-a-post-transplant-complication
FDA Approves Incyte/Syndax Partnered Drug ...
08/15/2024 14:11:20

The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at...

rbc-capital-maintains-sector-perform-on-incyte-raises-price-target-to-67
RBC Capital Maintains Sector Perform on In...
08/15/2024 14:02:59

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $66...

Core News & Articles
Incyte, Syndax Secure FDA Approval For Nik...
08/14/2024 21:55:48

FDA has approved Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (G...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION